Showing 6971-6980 of 10817 results for "".
- Allergan Launches New Philanthropic Program Benefitting Kids with Upper Limb Spasticityhttps://practicaldermatology.com/news/allergan-launches-new-philanthropic-program-benefitting-kids-with-upper-limb-spasticity/2460274/Allergan is launching the Be The Difference philanthropic program to support children and their families who may benefit from treatment with Botox (onabotulinumtoxinA) for pediatric upper limb spasticity. Botox is approved to treat increased muscle stiffness in children 2 to 17 years of
- Ortho Dermatologics Opens 2020 Aspire Higher Scholarship Programhttps://practicaldermatology.com/news/ortho-dermatologics-opens-2020-aspire-higher-scholarship-program/2460273/Bausch Health Companies Inc. and its dermatology business, Ortho Dermatologics opened of the application process for its 2020 Aspire Higher scholarship program. The program, which began in 2012, will award nine students who have been treated for a dermatologic condition with a
- San Diego Dermatology Symposium to Debut in Mayhttps://practicaldermatology.com/news/san-diego-dermatology-symposium-to-debut-in-may/2460254/Dermatology is a rapidly evolving specialty on the forefront of research and treatment advancements. With the advent of new advances in medical, cosmetic, and surgical dermatology, new clinical recommendations for diagnosis and treatment of various dermatologic conditions are developed.
- South Beach Symposium Poised for 18th Miami Conferencehttps://practicaldermatology.com/news/south-beach-symposium-poised-for-18th-miami-conference/2460253/The 18th Annual South Beach Symposium takes place in Miami Beach next month. Organizers say the annual conference boasts an extensive agenda, with in-depth pre-conference offerings, and sessions topics covering the latest and most well-supported knowledge in clinical and aesthetic dermatology. Ro
- Patients Report 95 Percent Satisfaction Rate with Mohs Surgery for Melanomahttps://practicaldermatology.com/news/patients-report-95-percent-satisfaction-rate-with-mohs-surgery-for-melanoma-2/2460252/Patients who received Mohs surgery to treat melanoma reported a 95 percent long-term satisfaction rate with their results, according to a new study by UT Southwestern Medical Center dermatologists. The study, published in Dermatologic Surgery, is the first to poll pat
- Almirall on the Move with Three New Collabshttps://practicaldermatology.com/news/almirall-on-the-move-with-three-new-collabs/2460248/With three new strategic agreements, Almirall, S.A. is set to strengthen their early-stage research portfolio and expand their pipeline in medical dermatology. Alimirall and 23andMe have signed an agreement allowing Almirall to in-license 23
- It’s Gold and Silver for Sebacia with Sienna Acquisitionhttps://practicaldermatology.com/news/its-gold-and-silver-for-sebacia-with-sienna-acquisition/2460247/Mr. Chuck Abraham is the new Chief Executive Officer of Sebacia, Inc. Sebacia is preparing a targeted commercial launch of Sebacia Microparticles in the US for treatment of acne early in 2020 with plans to expand to additional territories later in th
- Amorepacific Shows Off Face Mask 3D Printing System and Flexible LED Beauty Device at CES 2020https://practicaldermatology.com/news/amorepacific-shows-off-face-mask-3d-printing-system-and-flexible-led-beauty-device-at-ces-2020/2460246/Amorepacific is presenting its 3D face mask printing system (IOPE Tailored 3D Mask) and flexible LED beauty device (MakeON Flexible LED Patch) at the Consumer Electronics Show 2020 (CES 2020) in Las Vegas. Created in collaboration with the 3D printing system developer Lincsolu
- The HydraFacial Company Takes on Scalp Healthhttps://practicaldermatology.com/news/the-hydrafacial-company-takes-on-scalp-health/2460245/The HydraFacial Company is launching
- Castle Creek Completes Acquisition of Fibrocell Sciencehttps://practicaldermatology.com/news/castle-creek-completes-acquisition-of-fibrocell-science/2460235/Castle Creek Pharmaceutical Holdings, Inc. completed the acquisition of Fibrocell Science, Inc. Both companies have advanced investigational therapies for the treatment of epidermolysis bullosa (EB) into late-stage clinical research. Prior to the acquisition, Fibrocell initiated a pivot